Emittent / Herausgeber: GBI Group / Schlagwort(e): Immobilien/Expansion GBI Group startet die Hochbauarbeiten für neues SMARTments connect in Bielefeld - Innovatives Beherbergungsangebot mit 223 Einheiten in bester Lage direkt am Hauptbahnhof 25.04.2024 / 07:50 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Bielefeld/Berlin, 25.04.2024. Mit der Grundsteinlegung startet der Projektentwickler GBI Group in Bielefeld offiziell die Hochbauarbeiten für sein neues Serviced Apartment-Projekt direkt am Hauptbahnhof. Dort entstehen bis Ende k...
Issuer: GBI Group / Key word(s): Real Estate/Expansion GBI Group starts building construction work for new SMARTments connect in Bielefeld - Innovative accommodation offer with 223 units in a prime location directly at the central railway station 25.04.2024 / 07:50 CET/CEST The issuer is solely responsible for the content of this announcement. Bielefeld/Berlin, 25.04.2024.With the laying of the foundation stone, project developer GBI Group is officially starting in Bielefeld the building construction work for its new serviced apartment project directly at the central rail...
A director at Kinder Morgan Inc sold 230,000 shares at 18.820USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
>Updating estimates on strategic realignment - We are updating our estimates (-10% in average EBITDA 2024-25e) and valuation (-26%) of Soltec following the reclassification of 2023 results and its strategic realignment (stricter focus on the tracker segment with a reduction in the construction service activity and more selective approach in Energy projects). The company will update its financial guidance for 2024 when releasing Q1 2024 results and could update its lon...
>Opinion Surperformance et OC 14.4 € maintenus - Les résultats du T1 24 sont ressortis un peu au-dessus de nos attentes mais globalement en ligne avec le consensus. Comme attendu, la stratégie de résilience du groupe lui permet de bénéficier, sur ce trimestre, de la progression des activités régulées grâce à la croissance de la base d’actifs. Cela a permis de largement compenser une activité de génération bénéficiant certes d’un bon niveau d’hydrométrie sur la péninsu...
>T1 2024 : prises de commandes supérieures de 9% aux attentes - Atlas Copco a publié hier, en journée, ses résultats T1 2024 (voir tableau en page 2).Les prises de commandes étaient en recul organique de 4% yoy (css à -12,7%) mais 9% au-dessus des attentes du consensus (Compressor Technique en recul de -1% en organique vs -12.9% attendus par le css).Le CA a progressé de 7% en organique (css à 5.6%), dont notamment 8% pour Compressor Technique, 9% pour Power ...
>Organic growth still very robust in Q1 at +16.5%, upside undermined by a forex impact of 5 pt - The group’s Q1 2024 revenues reached € 1,187.2m, i.e. +11.5% y-o-y and +16.5% y-o-y at cc (Q4 2023: +18.1% cc), with retail sales at € 1,071.4m, i.e. 17.9% y-o-y at cc (Q4 2023: +17.4%). The Visible Alpha consensus had pointed to revenues in the region of € 1,164m, with organic growth at 13.6% (and retail sales of around € 1,047m, +13.7%), while our revenue forecast was ...
EQS-News: Marinomed Biotech AG / Key word(s): Alliance Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios 25.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios Marinomed will apply the Marinosolv solubilization technology to improve target compounds with the goal of developing products with differentiated pharmacological profiles The project covers the proof-of-...
EQS-News: Marinomed Biotech AG / Schlagwort(e): Kooperation Marinomed Biotech AG schließt Solv4U Forschungs- und Entwicklungskooperation mit brasilianischem Pharmaunternehmen Aché Laboratórios 25.04.2024 / 07:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Marinomed Biotech AG schließt Solv4U Forschungs- und Entwicklungskooperation mit brasilianischem Pharmaunternehmen Aché Laboratórios Marinomed soll durch Anwendung der Marinosolv-Technologie ausgewählte Wirkstoffe verbessern, um Produkte zu entwickeln, die sich pharmakologisch ...
A director at Old Second Bancorp Inc sold 40,267 shares at 14.556USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
>Un T1 un peu meilleur qu’attendu - KONE a publié hier matin des résultats T1 un peu meilleurs qu’attendu. Les commandes progressent de 1.6% à changes constants (css à 0.9%), grâce notamment au segment modernisation qui progresse de plus de 10%. Le chiffre d’affaires a augmenté de 2.7% à changes constants au T1 (consensus : +2.3%), avec une Chine en recul de 4.9%. En termes d’activité, les nouveaux équipements reculent (-4.2% à changes constants), les services (+9%) e...
>Q1 2024: volumes at -4% for top line, but margins still very solid - The group’s Q1 2024 results, reported yesterday morning, were in line with expectations at the operating level. Revenues came in 2% lower in organic terms, with -4% of volume effect (4th straight quarter of negative volumes, after -2% in Q4) and +2% of price effect.Adjusted EBIT came to SEK 5.4bn, up 4.6%, while the margin narrowed 60bp to 15.4%, just ahead of expectations (15.2%). The acquisit...
>Near-term challenges remain, improvement thereafter unlikely to be pencilled in - VW held a CMD in China yesterday (PR link), where the OEM reaffirmed and detailed its "China for China" strategy in the country and its ambitions. In a nutshell, our view would be that there was not much news from VW, with the China story still requiring both a lot of faith and patience. As VW management once again seems to be emphasizing, the next two years (at least) will remain chall...
>A better-than-expected Q1 - Yesterday morning, KONE published Q1 results that were a shade better than expected. Order intake was up by 1.6% at constant currency (cons. at 0.9%), notably thanks to the modernisation segment which grew by more than 10%. Sales were up by 2.7% at constant currency in Q1 (consensus: +2.3%), with a 4.9% decline in China. In terms of activity, new equipment declined -4.2% at constant currency, while services (+9%) and modernisation (+5.3%)...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.